MIMETAS is a leading company in the field of 3D disease modeling, providing unmatched disease relevance, precision, and throughput. The company is dedicated to leveraging its 3D tissue expertise to offer tailored solutions for unique research questions in drug discovery and compound analysis.

MIMETAS

We strive to contribute to groundbreaking therapies with ourscreenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.

EASME - EU Executive Agency for SMEs

Zeeuws Investerings Fonds

Aglaia BioMedical Ventures

Metric
Company Name	MIMETAS
Symbol
MSH ID	COM:MIMETAS
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	NL
Stage	Grant
Employee Count	112
Website	mimetas.com
LinkedIn	mimetas
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	11.10K
Web Traffic Growth	0.98
Valuation
Raised Capital	3.46M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MIMETAS

MIMETAS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue